Header Logo

Connection

SETH LERNER to Adult

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Adult.
SETH LERNER
Connection Strength
0.660
Adult
  1. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
    View in: PubMed
    Score: 0.056
  2. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
    View in: PubMed
    Score: 0.042
  3. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422.
    View in: PubMed
    Score: 0.016
  4. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006 Nov 15; 12(22):6663-76.
    View in: PubMed
    Score: 0.016
  5. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2.
    View in: PubMed
    Score: 0.016
  6. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006 Dec; 50(6):1254-60; discussion 1261-2.
    View in: PubMed
    Score: 0.016
  7. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Jul; 48(1):69-76.
    View in: PubMed
    Score: 0.015
  8. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
    View in: PubMed
    Score: 0.014
  9. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
    View in: PubMed
    Score: 0.014
  10. Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 08 01; 7(8):e2425288.
    View in: PubMed
    Score: 0.014
  11. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 10; 134(4):596-601.
    View in: PubMed
    Score: 0.014
  12. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004 May; 171(5):1830-4.
    View in: PubMed
    Score: 0.014
  13. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
    View in: PubMed
    Score: 0.014
  14. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):626-30.
    View in: PubMed
    Score: 0.013
  15. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003 Dec; 170(6 Pt 1):2244-7.
    View in: PubMed
    Score: 0.013
  16. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
    View in: PubMed
    Score: 0.013
  17. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
    View in: PubMed
    Score: 0.013
  18. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.013
  19. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer. 2002 Dec 15; 95(12):2494-9.
    View in: PubMed
    Score: 0.012
  20. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002 Mar; 167(3):1475-81.
    View in: PubMed
    Score: 0.012
  21. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):16-22.
    View in: PubMed
    Score: 0.011
  22. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.011
  23. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
    View in: PubMed
    Score: 0.011
  24. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.011
  25. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.010
  26. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Feb; 161(2):500-4.
    View in: PubMed
    Score: 0.010
  27. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 1997 Oct; 15(10):3214-22.
    View in: PubMed
    Score: 0.009
  28. Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
    View in: PubMed
    Score: 0.008
  29. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016 06; 27(6):1100-1106.
    View in: PubMed
    Score: 0.008
  30. Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ. 2014 Dec; 29(4):739-45.
    View in: PubMed
    Score: 0.007
  31. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15; 120(8):1272-80.
    View in: PubMed
    Score: 0.007
  32. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
    View in: PubMed
    Score: 0.006
  33. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013 Jun; 111(8):1215-21.
    View in: PubMed
    Score: 0.006
  34. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
    View in: PubMed
    Score: 0.006
  35. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.005
  36. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.005
  37. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010 Sep; 58(3):374-83.
    View in: PubMed
    Score: 0.005
  38. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May; 183(5):1757-63.
    View in: PubMed
    Score: 0.005
  39. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
    View in: PubMed
    Score: 0.005
  40. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
    View in: PubMed
    Score: 0.005
  41. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.005
  42. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
    View in: PubMed
    Score: 0.005
  43. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13.
    View in: PubMed
    Score: 0.005
  44. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug; 182(2):459-65; discussion 465.
    View in: PubMed
    Score: 0.005
  45. Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience. Transplant Proc. 2009 Jun; 41(5):1713-6.
    View in: PubMed
    Score: 0.005
  46. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May; 103(10):1359-62.
    View in: PubMed
    Score: 0.005
  47. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
    View in: PubMed
    Score: 0.005
  48. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008 Feb; 71(2):302-7.
    View in: PubMed
    Score: 0.004
  49. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
    View in: PubMed
    Score: 0.004
  50. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.004
  51. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008 Feb; 101(4):450-4.
    View in: PubMed
    Score: 0.004
  52. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int. 2007 Nov; 100(5):1015-20.
    View in: PubMed
    Score: 0.004
  53. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007 Mar; 51(3):699-706; discussion 706-8.
    View in: PubMed
    Score: 0.004
  54. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3):538-42.
    View in: PubMed
    Score: 0.004
  55. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007 Jan; 51(1):152-60.
    View in: PubMed
    Score: 0.004
  56. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.004
  57. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007 Jan; 51(1):137-49; discussion 149-51.
    View in: PubMed
    Score: 0.004
  58. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.004
  59. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol. 2006 May; 175(5):1645-9; discussion 1649.
    View in: PubMed
    Score: 0.004
  60. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84.
    View in: PubMed
    Score: 0.004
  61. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93.
    View in: PubMed
    Score: 0.004
  62. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005 Apr; 29(4):443-51.
    View in: PubMed
    Score: 0.004
  63. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.003
  64. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.003
  65. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62.
    View in: PubMed
    Score: 0.003
  66. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.003
  67. Technical and logistical considerations of in situ split-liver transplantation for two adults: Part I. Creation of left segment II, III, IV and right segment I, V-VIII grafts. Liver Transpl. 2001 Dec; 7(12):1077-80.
    View in: PubMed
    Score: 0.003
  68. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001 Sep; 116(3):437-43.
    View in: PubMed
    Score: 0.003
  69. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6.
    View in: PubMed
    Score: 0.003
  70. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18; 93(8):597-604.
    View in: PubMed
    Score: 0.003
  71. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70.
    View in: PubMed
    Score: 0.003
  72. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
    View in: PubMed
    Score: 0.003
  73. Giant bilateral renal angiomyolipomas associated with tuberous sclerosis. Urology. 2001 Mar; 57(3):554.
    View in: PubMed
    Score: 0.003
  74. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 01; 97(1):256-63.
    View in: PubMed
    Score: 0.003
  75. Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg. 2000 Sep; 232(3):312-23.
    View in: PubMed
    Score: 0.003
  76. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun; 24(6):469-74.
    View in: PubMed
    Score: 0.003
  77. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):71-85.
    View in: PubMed
    Score: 0.003
  78. The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. Yonsei Med J. 1999 Apr; 40(2):118-23.
    View in: PubMed
    Score: 0.002
  79. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
    View in: PubMed
    Score: 0.002
  80. Chronic lymphocytic leukemia in the young patient. Semin Oncol. 1998 Feb; 25(1):107-16.
    View in: PubMed
    Score: 0.002
  81. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997 Oct; 11(10):1631-5.
    View in: PubMed
    Score: 0.002
  82. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
    View in: PubMed
    Score: 0.002
  83. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9.
    View in: PubMed
    Score: 0.002
  84. Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? Urology. 1995 Sep; 46(3):408-11.
    View in: PubMed
    Score: 0.002
  85. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995 Aug 15; 86(4):1298-300.
    View in: PubMed
    Score: 0.002
  86. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun; 10(3):187-93.
    View in: PubMed
    Score: 0.002
  87. L-asparaginase and PEG asparaginase--past, present, and future. Leuk Lymphoma. 1993; 10 Suppl:153-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.